Brief: Alteogen Announces Completion Of Phase 1 Clinical Trial Of Aflibercept Biosimilar In Wet AMD Patients
08/03/2021 13:17
March 8 (Reuters) - Alteogen Inc 196170.KQ :
* ALTEOGEN ANNOUNCES COMPLETION OF PHASE 1 CLINICAL TRIAL OF
AFLIBERCEPT BIOSIMILAR IN WET AMD PATIENTS
* ALTEOGEN INC - IN PHASE 1 CLINICAL TRIAL, ALTEOGEN
CONFIRMED
SAFETY AND EFFICACY OF ALT-L9 WERE SIMILAR TO THAT OF EYLEA
* ALTEOGEN INC - INTENDS TO PROVE SIMILARITY OF ALT-L9 WITH
EYLEA
THROUGH A REGISTRATIONAL PHASE 3 CLINICAL TRIAL
Source text for Eikon: ID:nBw71jQFBa
Further company coverage: 196170.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alteogen
See all newsDeals of the day-Mergers and acquisitions
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Brief: Alteogen To Invest 253 Billion Won In Construction Of New Factory
Brief: Alteogen Q2 Operating. Profit 34.2 Billion Won
Brief: Alteogen - Signs Exclusive License Agreement For Alt-B4 Recombinant Human Hyaluronidase